Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration

Daniel A. Wolf, Leah R. Hanson, Elena L. Aronovich, Zhenhong Nan, Walter C. Low, William H. Frey, R. Scott McIvor

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Here we provide the first evidence that therapeutic levels of a lysosomal enzyme can bypass the blood-brain barrier following intranasal administration α-l-iduronidase (IDUA) activity was detected throughout the brains of IDUA-deficient mice following a single intranasal treatment with concentrated Aldurazyme® (laronidase) and was also detected after intranasal treatment with an adeno-associated virus (AAV) vector expressing human IDUA. These results suggest that intranasal routes of delivery may be efficacious in the treatment of lysosomal storage disorders.

Original languageEnglish (US)
Pages (from-to)131-134
Number of pages4
JournalMolecular Genetics and Metabolism
Volume106
Issue number1
DOIs
StatePublished - May 1 2012

Fingerprint

Iduronidase
Intranasal Administration
Blood-Brain Barrier
Enzymes
Viruses
Dependovirus
Brain
Therapeutics

Keywords

  • Adeno-associated virus
  • Alpha-l-iduronidase
  • Blood-brain barrier
  • Intranasal delivery
  • Mucopolysaccharidosis
  • Neurological disease

Cite this

Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration. / Wolf, Daniel A.; Hanson, Leah R.; Aronovich, Elena L.; Nan, Zhenhong; Low, Walter C.; Frey, William H.; McIvor, R. Scott.

In: Molecular Genetics and Metabolism, Vol. 106, No. 1, 01.05.2012, p. 131-134.

Research output: Contribution to journalArticle

@article{53ab76ff50d04f9a851ba64499cf1185,
title = "Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration",
abstract = "Here we provide the first evidence that therapeutic levels of a lysosomal enzyme can bypass the blood-brain barrier following intranasal administration α-l-iduronidase (IDUA) activity was detected throughout the brains of IDUA-deficient mice following a single intranasal treatment with concentrated Aldurazyme{\circledR} (laronidase) and was also detected after intranasal treatment with an adeno-associated virus (AAV) vector expressing human IDUA. These results suggest that intranasal routes of delivery may be efficacious in the treatment of lysosomal storage disorders.",
keywords = "Adeno-associated virus, Alpha-l-iduronidase, Blood-brain barrier, Intranasal delivery, Mucopolysaccharidosis, Neurological disease",
author = "Wolf, {Daniel A.} and Hanson, {Leah R.} and Aronovich, {Elena L.} and Zhenhong Nan and Low, {Walter C.} and Frey, {William H.} and McIvor, {R. Scott}",
year = "2012",
month = "5",
day = "1",
doi = "10.1016/j.ymgme.2012.02.006",
language = "English (US)",
volume = "106",
pages = "131--134",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration

AU - Wolf, Daniel A.

AU - Hanson, Leah R.

AU - Aronovich, Elena L.

AU - Nan, Zhenhong

AU - Low, Walter C.

AU - Frey, William H.

AU - McIvor, R. Scott

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Here we provide the first evidence that therapeutic levels of a lysosomal enzyme can bypass the blood-brain barrier following intranasal administration α-l-iduronidase (IDUA) activity was detected throughout the brains of IDUA-deficient mice following a single intranasal treatment with concentrated Aldurazyme® (laronidase) and was also detected after intranasal treatment with an adeno-associated virus (AAV) vector expressing human IDUA. These results suggest that intranasal routes of delivery may be efficacious in the treatment of lysosomal storage disorders.

AB - Here we provide the first evidence that therapeutic levels of a lysosomal enzyme can bypass the blood-brain barrier following intranasal administration α-l-iduronidase (IDUA) activity was detected throughout the brains of IDUA-deficient mice following a single intranasal treatment with concentrated Aldurazyme® (laronidase) and was also detected after intranasal treatment with an adeno-associated virus (AAV) vector expressing human IDUA. These results suggest that intranasal routes of delivery may be efficacious in the treatment of lysosomal storage disorders.

KW - Adeno-associated virus

KW - Alpha-l-iduronidase

KW - Blood-brain barrier

KW - Intranasal delivery

KW - Mucopolysaccharidosis

KW - Neurological disease

UR - http://www.scopus.com/inward/record.url?scp=84860138173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860138173&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2012.02.006

DO - 10.1016/j.ymgme.2012.02.006

M3 - Article

VL - 106

SP - 131

EP - 134

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 1

ER -